Skip to content Skip to footer
Subscribe Now

NEWS

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for ~$800M
Shots: Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, incl. its lead asset gildeuretinol (ALK-001), expanding Tarsus’ presence in retina care As per the deal, Alkeus will receive ~$450M upfront ($270M cash + $180M in Tarsus stock priced at $61.38/share), plus ~$350M in regulatory & commercial milestones, & low single-digit tiered descending…
August 6, 2026
Alteogen Licenses ALT-B4 to a Global Pharmaceutical Company in a ~$365M Deal
Shots: Alteogen has entered into an exclusive license agreement with a global pharmaceutical company to develop & commercialize a SC formulation of a biologic product utilizing ALT-B4 (berahyaluronidase alfa) As per the deal, the company will acquire exclusive global rights to the SC formulation of a biologic product. In exchange, Alteogen will receive ~$365M, incl.…
August 6, 2026
Schrödinger and Bristol Myers Squibb Expand AI Collaboration with Bunsen
Shots: Schrödinger has entered into a strategic agreement with BMS to deploy Bunsen, its agentic AI co-scientist, across BMS's research organization, expanding the companies' long-standing partnership As per the deal, Schrödinger will work with BMS to develop new Bunsen capabilities alongside its computational technologies for large-scale chemical exploration & RetroSynth, its AI-driven synthesis planning platform …
August 6, 2026
BlueWind Medical Receives FDA Clearance for Revi Extend Implant
Shots: The US FDA has granted 510(k) clearance to Revi Extend, the next-generation implant for Revi System to treat urgency urinary incontinence (UUI), with the new implant offering an extended lifespan of 15yrs.Limited US launch planned for Q4’26 Built on Implantable Tibial Neuromodulation (ITNM), Revi System is designed to reduce the long-term treatment burden through…
August 6, 2026
Takeda
Takeda Reports US FDA Approval of Orzeyful (Oveporexton) for Narcolepsy Type 1
Shots: The US FDA has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. DEA scheduling decision is expected within 90 days, after which it will be available through a specialty pharmacy Approval was based on extensive data, incl. P-III (FirstLight & RadiantLight) trial assessing Orzeyful (BID) in…
August 6, 2026
Summit Therapeutics Initiates P-II/III (HARMONi-GU1) Trial of Ivonescimab + Enfortumab Vedotin in Bladder Cancer
Shots: Summit has initiated P-II/III (HARMONi-GU1) trial of ivonescimab + enfortumab vedotin (EV) against Keytruda + EV as first-line treatment of locally advanced or metastatic urothelial (bladder) cancer The global, multi-regional trial will enroll ~800 pts through P-III, with site activations beginning later this year. P-II will determine the recommended P-III dose of ivonescimab in…
August 5, 2026
Natera Seeks PMDA Approval for Signatera CDx in MIBC
Shots: Natera has submitted an application to Japan's PMDA seeking approval of Signatera as a companion diagnostic (CDx) for muscle-invasive bladder cancer (MIBC) The submission expands the company's presence in Japan, where Signatera became the country's first PMDA-approved molecular residual disease (MRD) test for colorectal cancer in Jun 2026 Application is supported by data from…
August 5, 2026
SOPHiA GENETICS and AstraZeneca Partner to Develop Companion Diagnostics for Precision Oncology
Shots: SOPHiA GENETICS has entered a global collaboration with AstraZeneca to develop, validate, & commercialize two companion diagnostics (CDx) supporting precision oncology therapies The multi-year collaboration will leverage SOPHiA’s decentralized clinical trial assays & CDx capabilities to advance development & commercialization of the CDx programs As per the deal, SOPHiA GENETICS will develop its Solid Tumor…
August 5, 2026
Load more